On September 13, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that the Company will participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and at the 3rd Annual Macrophage-directed Therapies Summit (Press release, Infinity Pharmaceuticals, SEP 13, 2021, View Source [SID1234587635]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details can be found below:

Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Format: Live presentation and 1-on-1 meetings
Date and Time: September 20th at 1:15pm ET; 1-on-1 meetings September 20 – 22
Webcast Link: View Source
3rd Annual Macrophage-directed Therapies Summit
Format: Seminar and panel discussion
Title: Evaluating the Synergistic Potential of Combination with Other Frontline Treatments to Distinguish the Best Combination Approach
Date and Time: September 30th, 4:00pm ET
Registration Link: View Source
The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.